Salts and Derivatives of Active Pharmaceutical Ingredients (API)
The salts of Active Pharmaceutical Ingredients (APIs) are compounds formed by the reaction of an acid with a base, resulting in an ionic equilibrium. These salts often improve the solubility and stability of APIs, facilitating their absorption in the body. API derivatives are chemical variants of an active ingredient that may have enhanced or modified properties to optimise therapeutic efficacy. API salts are used in the formulation of oral, injectable, and topical medications. Additionally, API derivatives can improve the pharmacokinetics of drugs, such as enabling controlled release of active substances.
At CymitQuimica, we provide API salts and derivatives with the necessary purity and quality for research and pharmaceutical formulation development.
Found 79347 products of "Salts and Derivatives of Active Pharmaceutical Ingredients (API)"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Risedronate Related Compound B ([3,6-Bis[(3-pyridinyl)methyl]-2,5-dihydroxy-2,5-dioxido-1,4,2,5-dioxadiphosphorinane-3,6-diyl]bis[phosphonic acid] disodium tetrahydrate salt)
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C14H16N2O12P4Na2·4H2OColor and Shape:White Fine PowderMolecular weight:527.96537Acetaminophen Related Compound B (N-(4-hydroxyphenyl)propanamide)
CAS:Aromatic cyclic amides (including cyclic carbamates) and their derivatives; salts thereofFormula:C9H11NO2Color and Shape:White Brown PowderMolecular weight:165.07898Famotidine Related Compound F (3-[[2-(diaminomethyleneamino)thiazol-4-yl]methylthio]propanoic acid)
CAS:Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structureFormula:C8H12N4O2S2Color and Shape:White PowderMolecular weight:260.04017Haloperidol Related Compound B (4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(2-fluorophenyl)butan-1-one)
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFormula:C21H23ClFNO2Color and Shape:White Off-White PowderMolecular weight:375.14013Budesonide Related Compound L (16α,17-[butylidenebis(oxy)]-21-hydroxypregna-1,4-diene-3,11,20-trione)
CAS:Adrenal cortical hormones and their derivatives nesoiFormula:C25H32O6Color and Shape:White PowderMolecular weight:428.21989Bis(2-ethylhexyl)maleate (Maleic acid, bis(2-ethylhexyl)ester)
CAS:Maleic acid not in us note 3 section 6Formula:C20H36O4Color and Shape:LiquidMolecular weight:340.51Travoprost
CAS:Prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analoguesFormula:C26H35F3O6Color and Shape:Colorless Clear Pale Yellow LiquidMolecular weight:500.23857Desogestrel Related Compound D (13-Ethyl-11-methylenegon-4-en-17-one)
CAS:Cyclanic, cyclenic or cycloterpenic ketones without other oxygen function not elsewhere specified or includedFormula:C20H28OColor and Shape:White Off-White Crystalline PowderMolecular weight:284.21402Lovastatin Epimer Mixture (Epilovastatin and Lovastatin 1:1 Mixture)
Lactones nesoiFormula:C24H36O5Color and Shape:PowderMolecular weight:404.25627Quetiapine Related Compound B (11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine dihydrochloride)
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C17H17N3S·2HClColor and Shape:Off-White PowderMolecular weight:295.11432Primidone Related Compound A (2-Ethyl-2-phenylmalonamide)
CAS:Aromatic cyclic amides (including cyclic carbamates) and their derivatives; salts thereofFormula:C11H14N2O2Color and Shape:White Crystalline PowderMolecular weight:206.10553Theophylline Related Compound C (N-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)formamide)
CAS:<p>Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, nesoi</p>Formula:C7H10N4O3Color and Shape:Off-White PowderMolecular weight:198.07529Pramipexole Related Compound F ((6S,7R)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-7-ol)
CAS:Compounds containing a benzothiazole ring-system (whether or not hydrogenated), not further fusedFormula:C10H17N3OSColor and Shape:Off-White SolidMolecular weight:227.10923Febuxostat Related Compound C (Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate)
CAS:<p>Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure</p>Formula:C14H12N2O3SColor and Shape:Off-White Fine PowderMolecular weight:288.05686Chloropropiophenone (1-(3-Chlorophenyl)propan-1-one)
CAS:Aromatic ketones without other oxygen function, nesoiFormula:C9H9ClOColor and Shape:White Yellow SolidMolecular weight:168.03419Perindopril Related Compound K ((3S,5aS,9aS,10aS)-3-methyldecahydropyrazino[1,2-a]indole-1,4-dione)
CAS:Lactams, nesoiFormula:C12H18N2O2Color and Shape:White PowderMolecular weight:222.13683Zolmitriptan Related Compound F (2,2'-[4-(Dimethylamino)butane-1,1-diyl]bis{5-[(S)-(2-oxooxazolidin-4-yl)methyl]-3-(2-dimethylaminoethyl)indole})
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C38H53N7O4Color and Shape:Orange PowderMolecular weight:671.4159Gatifloxacin Related Compound A (1-Cyclopropyl-6-fluoro-8-hydroxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid)
CAS:Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, nesoiFormula:C18H20FN3O4Color and Shape:Yellow SolidMolecular weight:361.14378Oxazepam Related Compound A (7-Chloro-5-phenyl-4,5-dihydro-1H-benzodiazepine-2,3-dione)
CAS:Heterocyclic compounds with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoiFormula:C15H11ClN2O2Color and Shape:White Off-White PowderMolecular weight:286.05091Levocabastine Related Compound A (1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic acid hydrochloride)
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFormula:C25H27FN2O2·HClColor and Shape:White PowderMolecular weight:406.20566
